Immunogenicity of mRNA-1273 COVID vaccine after 6 months surveillance in health care workers; a third dose is necessary.
Immunogenicity of mRNA-1273 COVID vaccine after 6 months surveillance in health care workers; a third dose is necessary.
复制标题
DOI：
10.1016/j.jinf.2021.08.031
复制
发表时间：
2021-11
期刊：
影响因子：
--
通讯作者：
Blairon L
中科院分区：
文献类型：
--
作者：
Tré-Hardy M;Cupaiolo R;Wilmet A;Antoine-Moussiaux T;Della Vecchia A;Horeanga A;Papleux E;Vekemans M;Beukinga I;Blairon L
目前关于接种 mRNA 疫苗（尤其是 mRNA-1273）后抗体动力学的数据很少。我们在此报告对一组接受 mRNA-1273 疫苗的医护人员 (HCW) 进行 6 个月随访后获得的数据的中期分析。这些新数据让我们更深入地了解是否需要以及哪些人需要注射第三剂。我们的研究比较了第一次注射后 2 周 (T1)、3 个月 (T3) 和 6 个月 (T4) 以及第二次注射后 2 周 (T2) 的抗 S 抗体动力学。 201 名参与的医护人员根据其初始血清学状况进行了分层。还通过医学调查问卷评估了疫苗的有效性。我们在此报告 T3 和 T4 之间抗体显着且具有统计学意义的下降 (P < 0.05)，尤其是在未接种疫苗的接种者中。对严重 COVID-19 疾病的潜在混杂因素或已知风险因素的分析并未显示对观察到的下降有任何影响。接种疫苗后六个月，我们的队列中仅报告了一种有症状的感染。在供应有限的环境下，我们的结果呼吁在未来几个月内，在疫苗接种前为血清阴性个体保留第三剂疫苗，特别是当血清学状态很容易获得时。
Scarce data are currently available on the kinetics of antibodies after vaccination with mRNA vaccines as a whole and, with mRNA-1273, in particular. We report here an ad-interim analysis of data obtained after a 6-month follow-up in a cohort of healthcare workers (HCWs) who received the mRNA-1273 vaccine. These new data provide more insight into whether and in whom a 3rd dose could be necessary. Our study compared the anti-S antibody kinetics at 2 weeks (T1), 3 months (T3) and 6 months (T4) after the first injection, and 2 weeks after the second injection (T2). The 201 participating HCWs were stratified according to their initial serological status. The vaccine effectiveness was also assessed through a medical questionnaire. We report here a marked and statistically significant antibody decrease (P < 0.05) between T3 and T4, especially in naïve vaccinees. The analysis of potential confounding factors or known risk factors for severe COVID-19 disease did not reveal any influence on the drop observed. Six-month after vaccination, only one, symptomatic, infection was reported in our cohort. In a supply-limited environment, our results plead for reserving the 3rd dose scheme, in the upcoming months, to seronegative individuals prior to vaccination, especially when the serological status is easily accessible.
登录
查看更多内容
DOI：
10.1056/nejmoa2109072
发表时间：
2021-10-14
期刊：
The New England journal of medicine
影响因子：
--
作者：
Bergwerk M;Gonen T;Lustig Y;Amit S;Lipsitch M;Cohen C;Mandelboim M;Levin EG;Rubin C;Indenbaum V;Tal I;Zavitan M;Zuckerman N;Bar-Chaim A;Kreiss Y;Regev-Yochay G
通讯作者：
Regev-Yochay G
DOI：
10.1056/nejmoa2035389
发表时间：
2021-02-04
期刊：
The New England journal of medicine
影响因子：
--
作者：
Baden LR;El Sahly HM;Essink B;Kotloff K;Frey S;Novak R;Diemert D;Spector SA;Rouphael N;Creech CB;McGettigan J;Khetan S;Segall N;Solis J;Brosz A;Fierro C;Schwartz H;Neuzil K;Corey L;Gilbert P;Janes H;Follmann D;Marovich M;Mascola J;Polakowski L;Ledgerwood J;Graham BS;Bennett H;Pajon R;Knightly C;Leav B;Deng W;Zhou H;Han S;Ivarsson M;Miller J;Zaks T;COVE Study Group
通讯作者：
COVE Study Group
影响因子：
6.8
作者：
Tre-Hardy, Marie;Wilmet, Alain;Blairon, Laurent
通讯作者：
Blairon, Laurent
影响因子：
64.5
作者：
Walls, Alexandra C.;Park, Young-Jun;Veesler, David
通讯作者：
Veesler, David
影响因子：
13.2
作者：
Favresse J;Bayart JL;Mullier F;Elsen M;Eucher C;Van Eeckhoudt S;Roy T;Wieers G;Laurent C;Dogné JM;Closset M;Douxfils J
通讯作者：
Douxfils J